p300 knockout promotes butyrate resistance

Journal of Cancer

Volumn 8, Issue 17, 2017, Pages 3405-3409

  Lazarova, Darina L ^a   Bordonaro, Michael ^a  

^a Janet Weis Children s Hospital   (United States)

Author keywords

Butyrate; CBP; Colorectal cancer; p300; Resistance

Indexed keywords

BUTYRIC ACID; CASPASE; E1A ASSOCIATED P300 PROTEIN; WNT PROTEIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; D10 CELL LINE; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE INACTIVATION; HCT 116 CELL LINE; MICROARRAY ANALYSIS; STABLE TRANSFECTION; UPREGULATION; WNT SIGNALING;

EID: 85029697576     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.21145     Document Type: Article

References (16)

1. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition [EPIC]: an observational study. Lancet 2003; 361:1496-501.
2. Bordonaro M, Lazarova D, Sartorelli AC. Hyperinduction of WNT signaling: a new paradigm for the treatment of colorectal cancer? Oncol Res 2008; 17:1-9.
3. Bordonaro M, Lazarova DL, Sartorelli AC. The activation of beta-catenin by WNT signaling mediates the effects of histone deacetylase inhibitors. Exp Cell Res 2007; 313:1652-66.
4. Chiaro C, Lazarova DL, Bordonaro M. Tcf3 and cell cycle factors contribute to butyrate resistance in colorectal cancer cells. Biochem Biophys Res Commun 2012; 428:121-6.
5. Lazarova DL, Chiaro C, Wong T, et al. CBP activity mediates effects of the histone deacetylase inhibitor butyrate on Wnt activity and apoptosis in colon cancer cells. J. Cancer 2013; 4:481-90.
6. Lazarova DL, Wong T, Chiaro C, et al. p300 influences butyrate-mediated WNT hyperactivation in colorectal cancer cells. J Cancer 2013; 4:491-501.
7. Lazarova D, Lee A, Wong T, et al. Modulation of Wnt activity and cell physiology by butyrate in LT97 microadenoma cells. J. Cancer 2014; 5: 203-13.
8. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of ß-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 2004; 101:12682-7.
9. Krubasik D, Iyer NG, English WR, et al. Absence of p300 induces cellular phenotype changes characteristic of epithelial to mesenchyme transition. Br J Cancer 2006; 94:1326-1332.
10. Lazarova DL, Chiaro C, Bordonaro M. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells. BMC Research Notes 2014; 7:226.
11. Lazarova DL, Bordonaro M. Extreme fluctuations in Wnt/beta-catenin signaling as an approach for colon cancer prevention and therapy. Advanced Studies in Biology 2012; 4: 351-62.
12. Ionov Y, Matsui S-I, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. PNAS 2004; 101:1273-1278.
13. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science 2015; 349: 1483-8.
14. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225-31.
15. Bryan EJ, Jokubaitis VJ, Chamberlain NL, et al. Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int J Cancer 2002; 102:137-141.
16. Huh JW, Kim HC, Kim SH, et al. Prognostic impact of p300 expression in patients with colorectal cancer. J Surg Oncol 2013; 108:374-7.